Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Rani Therapeutics reports Q2 EPS (12c), consensus (18c) » 16:25
09/13/21
09/13
16:25
09/13/21
16:25
RANI

Rani Therapeutics

$21.06 /

+0.85 (+4.21%)

Reports Q2 revenue…

Reports Q2 revenue $1.96M, consensus $490,000. "This is an exciting phase for Rani following a successful IPO, which puts us in position to achieve our goals, including scaling and optimizing our manufacturing process, establishing the regulatory pathway for our capsule technology, and advancing our pipeline with clinical and development milestones," said Talat Imran, CEO of Rani Therapeutics. "We are committed to making oral biologics a reality, and we are looking forward to creating value along the way for both patients and shareholders."

ShowHide Related Items >><<
RANI Rani Therapeutics
$21.06 /

+0.85 (+4.21%)

RANI Rani Therapeutics
$21.06 /

+0.85 (+4.21%)

08/25/21 BTIG
Rani Therapeutics initiated with a Buy at BTIG
08/25/21 Canaccord
Rani Therapeutics initiated with Buy, $29 target at Canaccord
08/25/21 Canaccord
Rani Therapeutics initiated with a Buy at Canaccord
08/24/21 BofA
Rani Therapeutics initiated with a Buy at BofA
  • 30
    Jul
RANI Rani Therapeutics
$21.06 /

+0.85 (+4.21%)

Hot Stocks
Rani Therapeutics appoints Eric Groen as General Counsel » 08:11
09/09/21
09/09
08:11
09/09/21
08:11
RANI

Rani Therapeutics

$19.32 /

+0.7 (+3.76%)

Rani Therapeutics…

Rani Therapeutics appointed Eric Groen as General Counsel. Groen Prior to joining Rani, Groen served in various domestic and international roles of increasing responsibility over nearly 20 years at Amgen. Most recently, he served as regional general counsel to Amgen's commercial business in Canada, Latin America, Middle East and Africa.

ShowHide Related Items >><<
RANI Rani Therapeutics
$19.32 /

+0.7 (+3.76%)

08/25/21 BTIG
Rani Therapeutics initiated with a Buy at BTIG
08/25/21 Canaccord
Rani Therapeutics initiated with Buy, $29 target at Canaccord
08/25/21 Canaccord
Rani Therapeutics initiated with a Buy at Canaccord
08/24/21 BofA
Rani Therapeutics initiated with a Buy at BofA
  • 30
    Jul
RANI Rani Therapeutics
$19.32 /

+0.7 (+3.76%)

Over a month ago
Initiation
Rani Therapeutics initiated with a Buy at BTIG » 07:45
08/25/21
08/25
07:45
08/25/21
07:45
RANI

Rani Therapeutics

$17.75 /

+0.72 (+4.23%)

BTIG analyst Robert…

BTIG analyst Robert Hazlett initiated coverage of Rani Therapeutics with a Buy rating and $24 price target. The company is "bringing the promise of broad-scale oral biologics to the fore", the analyst tells investors in a research note, stating that its most advanced program - RT-101 - has helped establish proof-of-principle for the RaniPill capsule technologies. Hazlett adds that he sees a billion dollar peak revenue potential for Rani's RT-102, RT-109, RT-105, and the diabetes molecules.

ShowHide Related Items >><<
RANI Rani Therapeutics
$17.75 /

+0.72 (+4.23%)

08/25/21 Canaccord
Rani Therapeutics initiated with Buy, $29 target at Canaccord
08/25/21 Canaccord
Rani Therapeutics initiated with a Buy at Canaccord
08/24/21 BofA
Rani Therapeutics initiated with a Buy at BofA
08/24/21 Stifel
Rani Therapeutics initiated with a Buy at Stifel
  • 30
    Jul
RANI Rani Therapeutics
$17.75 /

+0.72 (+4.23%)

Initiation
Rani Therapeutics initiated with Buy, $29 target at Canaccord » 07:16
08/25/21
08/25
07:16
08/25/21
07:16
RANI

Rani Therapeutics

$17.75 /

+0.72 (+4.23%)

Canaccord analyst…

Canaccord analyst Michelle Gilson initiated coverage of Rani Therapeutics with a Buy rating and $29 price target. The analyst says Rani shares offer investors an opportunity to gain exposure to a clinical-stage company developing a "broad platform technology poised to disrupt the field of pain-free, oral biologics delivery." RaniPill is a reasonably-sized robotic pill device that is swallowed and activated in the small intestine, where there are no sharp pain receptors and is differentiated from competitive oral delivery technologies by the high bioavailability achieved, Gilson As previously reported,

ShowHide Related Items >><<
RANI Rani Therapeutics
$17.75 /

+0.72 (+4.23%)

08/25/21 Canaccord
Rani Therapeutics initiated with a Buy at Canaccord
08/24/21 BofA
Rani Therapeutics initiated with a Buy at BofA
08/24/21 Stifel
Rani Therapeutics initiated with a Buy at Stifel
08/24/21 Cantor Fitzgerald
Rani Therapeutics initiated with an Overweight at Cantor Fitzgerald
  • 30
    Jul
RANI Rani Therapeutics
$17.75 /

+0.72 (+4.23%)

Initiation
Rani Therapeutics initiated with a Buy at Canaccord » 07:03
08/25/21
08/25
07:03
08/25/21
07:03
RANI

Rani Therapeutics

$17.75 /

+0.72 (+4.23%)

Canaccord analyst…

Canaccord analyst Michelle Gilson initiated coverage of Rani Therapeutics with a Buy rating and $29 price target.

ShowHide Related Items >><<
RANI Rani Therapeutics
$17.75 /

+0.72 (+4.23%)

08/24/21 BofA
Rani Therapeutics initiated with a Buy at BofA
08/24/21 Stifel
Rani Therapeutics initiated with a Buy at Stifel
08/24/21 Cantor Fitzgerald
Rani Therapeutics initiated with an Overweight at Cantor Fitzgerald
08/24/21 BofA
Rani Therapeutics initiated with a Buy at BofA
  • 30
    Jul
RANI Rani Therapeutics
$17.75 /

+0.72 (+4.23%)

Initiation
Rani Therapeutics initiated with a Buy at BofA » 07:41
08/24/21
08/24
07:41
08/24/21
07:41
RANI

Rani Therapeutics

$17.00 /

+0.89 (+5.52%)

BofA analyst Geoff…

BofA analyst Geoff Meacham initiated coverage of Rani Therapeutics with a Buy rating and $23 price target. Rani's approach in oral administration of injectable drugs is differentiated from competitors which have historically used molecular engineering of the reference drug as a strategy, the analyst tells investors in a research note. If the company is successful, it could "revolutionize" the delivery of complex biologics such as peptides and antibodies, Meacham adds, estimating its initial pipeline therapies providing more than $5B in peak sales.

ShowHide Related Items >><<
RANI Rani Therapeutics
$17.00 /

+0.89 (+5.52%)

08/24/21 Stifel
Rani Therapeutics initiated with a Buy at Stifel
08/24/21 Cantor Fitzgerald
Rani Therapeutics initiated with an Overweight at Cantor Fitzgerald
08/24/21 BofA
Rani Therapeutics initiated with a Buy at BofA
  • 30
    Jul
RANI Rani Therapeutics
$17.00 /

+0.89 (+5.52%)

Initiation
Rani Therapeutics initiated with a Buy at Stifel » 06:20
08/24/21
08/24
06:20
08/24/21
06:20
RANI

Rani Therapeutics

$17.00 /

+0.89 (+5.52%)

Stifel analyst Annabel…

Stifel analyst Annabel Samimy initiated coverage of Rani Therapeutics with a Buy rating and $24 price target. Rani has a disruptive platform offering a technological, rather than pharmacological, approach to delivery, and Samimy thinks Rani has established a platform that generates value-driving catalysts and avenues for sustained growth, the analyst tells investors in a research note.

ShowHide Related Items >><<
RANI Rani Therapeutics
$17.00 /

+0.89 (+5.52%)

08/24/21 Cantor Fitzgerald
Rani Therapeutics initiated with an Overweight at Cantor Fitzgerald
08/24/21 BofA
Rani Therapeutics initiated with a Buy at BofA
  • 30
    Jul
RANI Rani Therapeutics
$17.00 /

+0.89 (+5.52%)

Initiation
Rani Therapeutics initiated with an Overweight at Cantor Fitzgerald » 06:15
08/24/21
08/24
06:15
08/24/21
06:15
RANI

Rani Therapeutics

$17.00 /

+0.89 (+5.52%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Brandon Folkes initiated coverage of Rani Therapeutics with an Overweight rating and $23 price target.

ShowHide Related Items >><<
RANI Rani Therapeutics
$17.00 /

+0.89 (+5.52%)

08/24/21 BofA
Rani Therapeutics initiated with a Buy at BofA
  • 30
    Jul
RANI Rani Therapeutics
$17.00 /

+0.89 (+5.52%)

Initiation
Rani Therapeutics initiated with a Buy at BofA » 06:05
08/24/21
08/24
06:05
08/24/21
06:05
RANI

Rani Therapeutics

$17.00 /

+0.89 (+5.52%)

BofA initiated coverage…

BofA initiated coverage of Rani Therapeutics with a Buy rating and $23 price target.

ShowHide Related Items >><<
  • 30
    Jul
RANI Rani Therapeutics
$17.00 /

+0.89 (+5.52%)

On The Fly
Opening Day: Sportradar files for IPO after SPAC talks break off » 08:27
08/21/21
08/21
08:27
08/21/21
08:27
ARBK

Argo Blockchain

/

+

, ARBKF

Argo Blockchain

$1.83 /

+0.15 (+8.93%)

, PRCT

Procept BioRobotics

/

+

, SRAD

Sportradar

/

+

, QNIU

Qiniu

/

+

, CMSL

Camposol

/

+

, SPRK

Spark Education

/

+

, SCAN

Perspectum Group

/

+

, AUTH

Authentic Brands Group

$8.01 /

+ (+0.00%)

, BLK

BlackRock

$917.42 /

+14.44 (+1.60%)

, SPG

Simon Property

$128.78 /

+0.35 (+0.27%)

, MS

Morgan Stanley

$100.71 /

+1.01 (+1.01%)

, GS

Goldman Sachs

$396.03 /

+2.76 (+0.70%)

, BCS

Barclays

$9.96 /

+0.01 (+0.10%)

, BAC

Bank of America

$40.38 /

+0.195 (+0.49%)

, MXCT

MaxCyte

$14.39 /

+0.61 (+4.43%)

, RXST

RxSight

$11.89 /

-0.175 (-1.45%)

, TNYA

Tenaya Therapeutics

$22.31 /

+1.41 (+6.75%)

, RANI

Rani Therapeutics

$16.11 /

-0.93 (-5.46%)

, NUVL

Nuvalent

$27.21 /

+0.44 (+1.64%)

, ICVX

Icosavax

$34.69 /

+0.69 (+2.03%)

, RSKD

Riskified

$28.61 /

+1.445 (+5.32%)

, OMGA

Omega Therapeutics

$21.94 /

-0.09 (-0.41%)

, IMRX

Immuneering

$30.23 /

-0.53 (-1.72%)

, INAB

In8bio

$7.64 /

-0.22 (-2.80%)

, HOOD

Robinhood

$42.62 /

-1.99 (-4.46%)

, RLYB

Rallybio

$12.57 /

-0.23 (-1.80%)

, ABVC

ABVC BioPharma

$2.03 /

-0.12 (-5.58%)

In a quiet week for IPOs,…

ShowHide Related Items >><<
SPG Simon Property
$128.78 /

+0.35 (+0.27%)

RLYB Rallybio
$12.57 /

-0.23 (-1.80%)

MXCT MaxCyte
$14.39 /

+0.61 (+4.43%)

MS Morgan Stanley
$100.71 /

+1.01 (+1.01%)

INAB In8bio
$7.64 /

-0.22 (-2.80%)

ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

HOOD Robinhood
$42.62 /

-1.99 (-4.46%)

GS Goldman Sachs
$396.03 /

+2.76 (+0.70%)

BLK BlackRock
$917.42 /

+14.44 (+1.60%)

BCS Barclays
$9.96 /

+0.01 (+0.10%)

BAC Bank of America
$40.38 /

+0.195 (+0.49%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

ARBK Argo Blockchain
/

+

ARBKF Argo Blockchain
$1.83 /

+0.15 (+8.93%)

06/01/21 H.C. Wainwright
Argo Blockchain initiated with a Buy at H.C. Wainwright
PRCT Procept BioRobotics
/

+

SRAD Sportradar
/

+

QNIU Qiniu
/

+

CMSL Camposol
/

+

SPRK Spark Education
/

+

SCAN Perspectum Group
/

+

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

BLK BlackRock
$917.42 /

+14.44 (+1.60%)

07/15/21 Credit Suisse
BlackRock price target lowered to $1,000 from $1,011 at Credit Suisse
07/15/21 Argus
BlackRock price target raised to $975 from $950 at Argus
07/15/21 Deutsche Bank
BlackRock price target lowered to $1,001 from $1,018 at Deutsche Bank
07/15/21 BMO Capital
BlackRock price target raised to $803 from $773 at BMO Capital
SPG Simon Property
$128.78 /

+0.35 (+0.27%)

08/16/21 Truist
Simon Property price target raised to $136 from $130 at Truist
08/13/21 Truist
Simon Property price target raised to $136 from $130 at Truist
08/13/21 Morgan Stanley
Simon Property price target raised to $161 from $150 at Morgan Stanley
08/04/21 BofA
Simon Property upgraded to Buy from Neutral at BofA
MS Morgan Stanley
$100.71 /

+1.01 (+1.01%)

08/13/21 Seaport Global
Morgan Stanley downgraded to Neutral at Seaport Global on valuation
08/13/21 Seaport Global
Morgan Stanley downgraded to Neutral from Buy at Seaport Global
07/19/21 Citi
Morgan Stanley price target raised to $97 from $88 at Citi
07/16/21 Argus
Morgan Stanley price target raised to $105 from $93 at Argus
GS Goldman Sachs
$396.03 /

+2.76 (+0.70%)

07/14/21 Oppenheimer
Goldman Sachs price target raised to $540 from $493 at Oppenheimer
07/14/21 Credit Suisse
Goldman Sachs price target raised to $425 from $420 at Credit Suisse
07/14/21 Mizuho
Affirm selloff on Apple competition fears overblown, says Mizuho
07/14/21 Piper Sandler
Goldman Sachs price target raised to $435 from $420 at Piper Sandler
BCS Barclays
$9.96 /

+0.01 (+0.10%)

08/02/21 RBC Capital
Barclays price target raised to 190 GBp from 180 GBp at RBC Capital
07/30/21 Morgan Stanley
Barclays price target raised to 205 GBp from 200 GBp at Morgan Stanley
07/29/21 UBS
Barclays price target raised to 220 GBp from 210 GBp at UBS
07/29/21 Deutsche Bank
Barclays price target raised to 240 GBp from 230 GBp at Deutsche Bank
BAC Bank of America
$40.38 /

+0.195 (+0.49%)

07/19/21 Odeon Capital
Bank of America downgraded to Hold from Buy at Odeon Capital
07/06/21 Keefe Bruyette
Bank of America assumed with a Market Perform at Keefe Bruyette
06/02/21 Truist
Bank of America initiated with a Buy at Truist
05/04/21
Fly Intel: Top five analyst downgrades
MXCT MaxCyte
$14.39 /

+0.61 (+4.43%)

RXST RxSight
$11.89 /

-0.175 (-1.45%)

TNYA Tenaya Therapeutics
$22.31 /

+1.41 (+6.75%)

RANI Rani Therapeutics
$16.11 /

-0.93 (-5.46%)

NUVL Nuvalent
$27.21 /

+0.44 (+1.64%)

ICVX Icosavax
$34.69 /

+0.69 (+2.03%)

RSKD Riskified
$28.61 /

+1.445 (+5.32%)

OMGA Omega Therapeutics
$21.94 /

-0.09 (-0.41%)

IMRX Immuneering
$30.23 /

-0.53 (-1.72%)

INAB In8bio
$7.64 /

-0.22 (-2.80%)

HOOD Robinhood
$42.62 /

-1.99 (-4.46%)

08/17/21 Redburn
Redburn starts Robinhood at Buy with fair value implying 29% upside
08/17/21 Redburn
Robinhood initiated with a Buy at Redburn
08/05/21 Wolfe Research
Robinhood initiated with a Peer Perform at Wolfe Research
07/29/21
Fly Intel: Top five analyst initiations
RLYB Rallybio
$12.57 /

-0.23 (-1.80%)

ABVC ABVC BioPharma
$2.03 /

-0.12 (-5.58%)

SPG Simon Property
$128.78 /

+0.35 (+0.27%)

MS Morgan Stanley
$100.71 /

+1.01 (+1.01%)

HOOD Robinhood
$42.62 /

-1.99 (-4.46%)

GS Goldman Sachs
$396.03 /

+2.76 (+0.70%)

BLK BlackRock
$917.42 /

+14.44 (+1.60%)

BCS Barclays
$9.96 /

+0.01 (+0.10%)

BAC Bank of America
$40.38 /

+0.195 (+0.49%)

ABVC ABVC BioPharma
$2.03 /

-0.12 (-5.58%)

  • 30
    Jul
  • 30
    Jul
  • 30
    Jul
  • 30
    Jul
  • 29
    Jul
  • 30
    Jul
  • 30
    Jul
  • 29
    Jul
  • 30
    Jul
  • 29
    Jul
  • 29
    Jul
  • 29
    Jul
  • 16
    Jul
  • 19
    Nov
  • 13
    Nov
SRAD Sportradar
/

+

MS Morgan Stanley
$100.71 /

+1.01 (+1.01%)

HOOD Robinhood
$42.62 /

-1.99 (-4.46%)

GS Goldman Sachs
$396.03 /

+2.76 (+0.70%)

BLK BlackRock
$917.42 /

+14.44 (+1.60%)

BCS Barclays
$9.96 /

+0.01 (+0.10%)

BAC Bank of America
$40.38 /

+0.195 (+0.49%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

SRAD Sportradar
/

+

SPG Simon Property
$128.78 /

+0.35 (+0.27%)

RXST RxSight
$11.89 /

-0.175 (-1.45%)

QNIU Qiniu
/

+

HOOD Robinhood
$42.62 /

-1.99 (-4.46%)

GS Goldman Sachs
$396.03 /

+2.76 (+0.70%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

SPG Simon Property
$128.78 /

+0.35 (+0.27%)

MS Morgan Stanley
$100.71 /

+1.01 (+1.01%)

HOOD Robinhood
$42.62 /

-1.99 (-4.46%)

GS Goldman Sachs
$396.03 /

+2.76 (+0.70%)

BAC Bank of America
$40.38 /

+0.195 (+0.49%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.